Pharmacometabolomics of treatment response to antihypertensive drugs: a systematic review.

J HypertensJun 20, 2026 (epub)
Clinical ResearchCardiologyInternal Medicine (General)

Elahe Zare Borzeshi, Merys Valdez, Alida Kindt et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the role of pharmacometabolomics in predicting responses to antihypertensive drugs in patients with primary hypertension. Out of 2577 screened articles, five studies were included, identifying 46 metabolites significantly associated with blood pressure responses to various antihypertensive medications. Key metabolites included arachidonic acid and sphingosine-1-phosphate.

Key findings

  • 46 metabolites were significantly associated with blood pressure responses to antihypertensive drugs.
  • Key predictive metabolites included arachidonic acid and sphingosine-1-phosphate.
  • Metabolites affected responses across fatty acid metabolism, sphingolipid metabolism, and the TCA cycle.

Why it matters

Understanding the metabolic biomarkers linked to antihypertensive drug response can help clinicians tailor treatments to individual patients, potentially improving blood pressure control and reducing cardiovascular risk.

Source

PubMed · PMID 42319207

Published in J Hypertens. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.